Story · Medicine & Biotech
Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial
3 outlets · first reported by MedPage Today on · latest · 19 hours of coverage
(MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week... (MedPage Today)
Coverage, in order
-
Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial(MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week...
-
OW2026: Striking BMI Outcomes with Tirzepatide in Teens
The possibility of life-changing treatment for adolescents with significant obesity is coming into sharp focus at ObesityWeek. New results from the SURMOUNT-ADOLESCENTS trial, presented at OW2026 and published in JAMA yesterday, show striking outcomes with tirzepatide. Perhaps most remarkable…
-
Tirzepatide Cuts Teen BMI by 18.5% in JAMA Trial—But What About Safety, Cost and Lifelong Treatment?
Tirzepatide Cuts Teen BMI by 18.5% in JAMA Trial—But What About Safety, Cost and Lifelong Treatment?
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.